Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
InhaleRx Limited ( (AU:IRX) ) has shared an announcement.
InhaleRx Limited has made significant progress in its clinical development programs for IRX-211 and IRX-616a, with approvals and manufacturing processes underway for upcoming trials. The company is aligning with FDA guidelines and has received Human Research Ethics Committee approvals for both drugs, marking a crucial step towards clinical trials. The focus remains on achieving FDA approval while maintaining cost efficiency and rapid development timelines, with IRX-211 poised to address a significant market gap in non-opioid treatments for breakthrough cancer pain.
More about InhaleRx Limited
InhaleRx Limited is an Australian drug development company focused on creating novel inhaled medicines. The company is currently developing two drugs: IRX-211 for breakthrough cancer pain and IRX-616a for panic disorder. InhaleRx aims to secure New Drug Approvals from the US FDA for these treatments, positioning itself as a pioneer in the inhaled cannabinoid medication market for pain and anxiety-related conditions.
Average Trading Volume: 152,017
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$7.19M
For a thorough assessment of IRX stock, go to TipRanks’ Stock Analysis page.